ABSTRACT
AIM: The present study aimed to examine whether plasma osteopontin (pOPN) and symmetric dimethylarginine (pSDMA) are useful biomarkers of renal dysfunction in children with solitary functioning kidney (SFK). METHODS: We measured circulating pOPN and pSDMA in 51 patients with SFK and no other urinary defects. Patients were subdivided into two groups: primary SFK (pSFK) - unilateral renal agenesis (URA), and secondary SFK (sSFK) - unilateral nephrectomy. The control group (C) contained 21 healthy children, with mean age 9.92 ± 4.85 years. Immunoenzymatic ELISA commercial kits were used to measure pOPN and pSDMA concentrations. RESULTS: Plasma osteopontin and pSDMA levels in children with SFK were higher than those in healthy participants (p < 0.05). There was no difference in pOPN and pSDMA concentrations between patients with pSFK and those with sSFK (p > 0.05). Receiver operator characteristic analyses performed to define the diagnostic efficiency of serum creatinine, pOPN and pSDMA in identifying children with C(cr) < 90 mL/min/1.73 m(2) among all examined children revealed no differences between all three AUCs (p > 0.05). CONCLUSION: Increased pOPN and pSDMA levels were observed in children with SFK. Both pOPN and pSDMA correlated with eGFR; however, the sensitivity and specificity of those markers were not better than those of creatinine.
Subject(s)
Arginine/analogs & derivatives , Kidney Diseases/diagnosis , Kidney Function Tests/methods , Osteopontin/blood , Adolescent , Arginine/blood , Biomarkers/blood , Case-Control Studies , Child , Child, Preschool , Congenital Abnormalities/blood , Creatinine/blood , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Infant , Kidney/abnormalities , Kidney Diseases/blood , Kidney Diseases/complications , Kidney Diseases/congenital , Kidney Diseases/etiology , Kidney Diseases/surgery , Male , Nephrectomy , ROC Curve , Retrospective StudiesABSTRACT
AIM: The purpose of the study was to investigate serum concentrations of the monocyte chemoattractant protein-1 (MCP-1) and high-sensitivity CRP (hs-CRP) in children with hyperuricemia and to evaluate its association with obesity. PATIENTS AND METHODS: The study involved 52 hyperuricemic patients with mean age of 15.53 ± 1.7 years. Twenty-seven healthy individuals with normal serum uric acid (SUA) level were selected as the control group (C). Serum MCP-1 and hs-CRP were measured by enzyme-linked immunosorbent assay (ELISA) and immunonephelometry, respectively. RESULTS: Hyperuricemic patients showed increased sMCP-1 (median: 69.58 pg/mL) and hs-CRP (median: 0.53 mg/L) vs. controls (48.39 pg/mL, 0.24 mg/L; respectively) (p < 0.01). The obese children also presented significantly higher levels of sMCP-1 and hs-CRP (median, 81.69 and 1.18 mg/L, respectively) in comparison with nonobese (median, 59.62 and 0.41 mg/L, respectively; p < 0.01). Only hs-CRP correlated positively with body mass index Z-score (r = 0.33, p < 0.05). Receiver operator characteristic analyses checking the sensitivity and specificity of examined markers for hyperuricemia revealed the higher area under the curve (AUC) for sMCP-1; however, the difference between AUC for sMCP-1 and for hs-CRP was not significant (p > 0.05). CONCLUSION: Serum MCP-1 and hs-CRP are elevated in hyperuricemic patients, but the role of obesity in inflammation markers needs further investigation.
